EJNMMI Research最新文献

{"title":"Diagnostic and prognostic role of ¹⁸F-FDG PET/CT for sarcomatoid differentiation in renal cell carcinoma.","authors":"Ritai Na, Zhao Chen, Yongshun Liu, Qianrui Chen, Qi Yang, Yongkang Qiu, Tianyao Wang, Lele Song, Sitong Wu, Wenpeng Huang, Xinyao Sun, Shaozhong Xian, Lei Kang","doi":"10.1186/s13550-025-01206-w","DOIUrl":"10.1186/s13550-025-01206-w","url":null,"abstract":"<p><strong>Background: </strong>Sarcomatoid differentiation is an invasive dedifferentiated feature of tumor and associated with poor prognosis in renal cell carcinoma (RCC) patients. This study aimed to evaluate the utility of ¹⁸F-FDG PET/CT in predicting sarcomatoid differentiation in RCC and its potential prognostic value.</p><p><strong>Results: </strong>This retrospective study assessed newly diagnosed sarcomatoid differentiation renal cell carcinoma (SDRCC) patients who were staged using ¹⁸F-FDG PET/CT. Patients were categorized into high-grade sarcomatoid differentiation RCC (HG-SDRCC), low-grade sarcomatoid differentiation RCC (LG-SDRCC), and non-sarcomatoid differentiation RCC (non-SDRCC). The maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were compared. Overall survival (OS) and disease-free survival (DFS) were analyzed. SUVmax, MTV, TLG, and SUVmean values were significantly higher in SDRCC compared to non-SDRCC (P < 0.05). Additionally, SUVmax, TLG, and SUVmean were significantly higher in HG-SDRCC compared to non-HG-SDRCC (P < 0.05). ROC curves revealed that SUVmax and SUVmean were effective for distinguishing HG-SDRCC from non-HG-SDRCC. The log-rank test identified SUVmax > 11, MTV > 95, TLG > 500, SUVmean > 5.2, invasion of peripheral tissue and/or organs, and metastasis as risk factors for SDRCC patients. Multivariate Cox proportional hazards model analyses indicated that TLG > 500 was a risk factor for poor DFS, while SUVmax > 11 and SUVmean > 5.2 were risk factors for poor OS.</p><p><strong>Conclusions: </strong>¹⁸F-FDG PET/CT can effectively differentiate HG-SDRCC with more aggressive malignancy. The prognostic model developed in this study demonstrates that metabolic parameters, particularly TLG for DFS and SUVmax/SUVmean for OS, serve as more robust predictors of patient outcomes than the degree of sarcomatoid differentiation.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"11"},"PeriodicalIF":3.1,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCR4-targeted PET imaging in rheumatoid arthritis: a novel approach for monitoring disease activity and therapeutic response.","authors":"Ya Han, Shuo Cao, Jie Liu, Binbin Ding, Shijie Wang, Jihong Pan, Yongpeng Ge, Kai Cheng, Lin Wang, Luna Ge","doi":"10.1186/s13550-025-01203-z","DOIUrl":"10.1186/s13550-025-01203-z","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a common chronic, inflammatory autoimmune disease, and early clinical diagnosis is crucial for its treatment. CXCR4 expression was characterized in arthritic mouse models and joints of RA patients, and [¹⁸ F]AIF-NOTA-QHA-04 specificity was assessed in non-malignant cells with elevated CXCR4 expression. This study explored the application of CXCR4-targeted PET probe [¹⁸ F]AIF-NOTA-QHA-04 in monitoring disease activity and therapeutic efficacy in RA. To this aim, the metabolic characteristics of [¹⁸ F]AIF-NOTA-QHA-04 and correlation of [¹⁸ F]AIF-NOTA-QHA-04 uptake with arthritis severity were evaluated by PET imaging in arthritic mice. [¹⁸ F]AIF-NOTA-QHA-04 potential in evaluating therapeutic efficacy was further investigated in arthritic mice following methotrexate (MTX) and etanercept (ETC) treatment.</p><p><strong>Results: </strong>CXCR4 expression was significantly increased in the inflamed joints of collagen-induced arthritis (CIA) and collagen-antibody induced arthritic (CAIA) mice, and in synovial tissues of RA patients. [¹⁸ F]AIF-NOTA-QHA-04 showed high specificity for CXCR4, with increased probe uptake in arthritic joints that was strongly correlated with arthritis severity scores. PET imaging revealed that increased uptake of [¹⁸ F]AIF-NOTA-QHA-04 in arthritic joints paralleled disease activity, with uptake decreasing upon remission. Furthermore, [¹⁸ F]AIF-NOTA-QHA-04 PET imaging provided earlier and more sensitive assessments of the efficacy of MTX and ETC compared to traditional methods.</p><p><strong>Conclusion: </strong>The CXCR4-targeted PET probe [¹⁸ F]AIF-NOTA-QHA-04 is a promising tool for RA diagnosis and monitoring, with high specificity and sensitivity. The potential of this probe as a biomarker for disease activity and therapeutic response underscores its value in personalized medication strategies for the management of RA.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"10"},"PeriodicalIF":3.1,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification in respiratory-gated PET acquisition: can data-driven methods replace device-based systems?-a comparative and retrospective study.","authors":"Laurentiu Agrigoroaie, Nadege Anizan, Camilo Garcia, Corinne Balleyguier, Théophraste Henry","doi":"10.1186/s13550-025-01195-w","DOIUrl":"10.1186/s13550-025-01195-w","url":null,"abstract":"<p><strong>Background: </strong>Device-based respiratory gating improves diagnostic and quantification accuracy in positron emission tomography (PET), but requires additional time to setup the device and the failure rate can be significant. Our aim was to internally validate the quantification performance of data-driven respiratory-gated PET imaging against the gold standard, the device-based method, in clinical oncological practice. We retrospectively analysed [18F]FDG PET/CT scans of patients from our centre with at least one measurable [18F]FDG-avid malignant lesion. All PET/CT acquisitions were performed on a Siemens Biograph 64 Vision 600 system with respiratory gating by belt and also by adding the data-driven gating with OncoFreeze AI™. We recorded the SUVmax and SUVpeak for up to a maximum of 5 lesions per patient. We computed the mean absolute bias between the two gating methods and the 95% confidence intervals (CI) at the cohort level and in subgroups.</p><p><strong>Results: </strong>Of the 692 consecutive patients screened for inclusion, 196 patients were analysed, from whom 536 lesions were measured. The mean absolute biases in the SUVmax and SUVpeak of lesions in the whole cohort were 3.8% (CI 3.4-4.2) and 2.1% (CI 1.9-2.4), respectively. At patient-level, 21% of them had at least one lesion with a SUVmax bias above 10%, while for SUVpeak this proportion was 5%. In the subgroup analysis by PERCIST criteria, only 2% of patients had significant bias in the SUVmax, and 0.5% in SUVpeak. There was no clinically significant effect of lesion size or anatomical site on SUV measurements between the two respiratory gating methods.</p><p><strong>Conclusion: </strong>Quantitative comparison of data-driven and device-based respiratory-gated PET scans revealed negligible differences, proving that data-driven respiratory gating is a reliable and accurate alternative to the device-based gating method in routine [18F]FDG-PET/CT oncological evaluation.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"9"},"PeriodicalIF":3.1,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11828764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous blood sampling for less invasive in vivo quantification of synaptic density with constant infusion of [¹⁸F]SynVesT-1 and PET.","authors":"Ruth H Asch, Mika Naganawa, Karina Moisieienko, Mia Weed, Michael Kapinos, Ming-Qiang Zheng, Ansel T Hillmer, Richard E Carson, Robert H Pietrzak, Irina Esterlis","doi":"10.1186/s13550-025-01200-2","DOIUrl":"10.1186/s13550-025-01200-2","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"8"},"PeriodicalIF":3.1,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11790547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of multi-parameter ¹²³I-MIBG scintigraphy in the differential diagnosis of Parkinson's disease.","authors":"Teng Xue, Ying Cui, Ying Kan, Guanyun Wang, Jigang Yang","doi":"10.1186/s13550-025-01197-8","DOIUrl":"10.1186/s13550-025-01197-8","url":null,"abstract":"<p><strong>Background: </strong>¹²³I-MIBG scintigraphy plays a significant role in diagnosing Parkinson's disease (PD), with most studies primarily targeting cardiac uptake and relying on traditional ratio-based parameters for assessment. However, due to variations in scanning conditions and image processing methodologies, the clinical utility of different parameters remains a subject of debate. This study aims to evaluate the diagnostic accuracy of multi-parameter ¹²³I-3-Iodobenzylguanidine (MIBG) scintigraphy and to identify the most reliable metrics for distinguishing PD from Parkinson-plus syndromes.</p><p><strong>Result: </strong>We recruited 56 PD patients and 44 non-PD controls, who underwent ¹²³I-MIBG scintigraphy and clinical evaluation. MIBG uptake and washout rates (WR) for the heart, salivary glands, and thyroid were assessed, with semi-quantitative methods used to calculate heart-to-mediastinum (H/M) and gland-to-background (P/B, S/B, T/B) ratios. Diagnostic efficacy was evaluated using receiver operating characteristic (ROC) curves. The H/M ratio and cardiac WR parameters scintigraphy exhibited excellent diagnostic efficacy for PD and PPS. The 4 h H/M ratio showed superior diagnostic performance with an area under the ROC curve (AUC) of 0.980. Background and time decay correction improved cardiac WR diagnostic performance (AUC = 0.963). Although P/B, S/B, and T/B ratios showed no significant differences for differential diagnosis, the WR values of the parotid and thyroid glands exhibited moderate diagnostic efficacy with AUCs of 0.648 and 0.638, respectively.</p><p><strong>Conclusion: </strong>The heart H/M ratio and cardiac WR in ¹²³I-MIBG scintigraphy show high diagnostic efficacy for both diagnosing and differentiating PD. Including cardiac WR in routine assessments is recommended. The diagnostic potential of WR in the parotid and thyroid glands also holds promise for PD diagnosis. Incorporating these parameters could enhance the accuracy of PD diagnosis, particularly in clinical scenarios where concurrent cardiac disease may confound the diagnosis.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"7"},"PeriodicalIF":3.1,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study.","authors":"Yilin Li, Rongxi Wang, Jingci Chen, Zhaohui Zhu, Yu Wang, Wenbin Ma","doi":"10.1186/s13550-025-01198-7","DOIUrl":"10.1186/s13550-025-01198-7","url":null,"abstract":"<p><strong>Background: </strong>Gliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of ⁶⁸Ga-NOTA-RM26 PET/CT imaging in glioma and analyze the relationship between the imaging characteristics and glioma grade, classification and molecular alterations.</p><p><strong>Results: </strong>Twenty-two patients were confirmed as glioma by surgery or biopsy. All patients exhibited ⁶⁸Ga-NOTA-RM26 uptake. SUV_max was chosen as the imaging marker for analysis. For all glioma patients, there were significant differences between grades (P = 0.047). For primary gliomas, SUV_max had good discrimination for both tumor classifications (P = 0.045) and grades (P = 0.03). There was a positive correlation (P < 0.01) between GRPR expression level and SUV_max. P53 mutations caused significant differences in SUV_max (P = 0.03).</p><p><strong>Conclusions: </strong>This study is the first application of ⁶⁸Ga-NOTA-RM26 in glioma patients and confirmed the safety and efficacy in glioma patients. ⁶⁸Ga-NOTA-RM26 PET/CT has potential value in tumor grade, classification, and molecular alterations.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT06412952. Registered 26 April 2024, https://clinicaltrials.gov/study/NCT06412952.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"6"},"PeriodicalIF":3.1,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-Pentixafor PET/CT for the assessment of therapeutic outcomes following superselective adrenal arterial embolization in patients with primary aldosteronism.","authors":"MengDan Li, Lili Guan, Lu Yang, WenBo Li, Zhu Xia, Min Mao, Hua Pang","doi":"10.1186/s13550-024-01194-3","DOIUrl":"10.1186/s13550-024-01194-3","url":null,"abstract":"<p><strong>Background: </strong>Superselective adrenal artery embolization (SAAE) represents a novel therapeutic strategy for managing primary aldosteronism (PA). Currently, the evaluation of its efficacy is primarily restricted to clinical indicators, with a notable deficiency in imaging evaluation methodologies. In recent years, several studies have investigated the application of ⁶⁸Ga-Pentixafor PET/CT for the classification of PA. However, there is a scarcity of specific research investigating the role of PET/CT in the evaluation of efficacy of this condition. Consequently, this study aims to evaluate the therapeutic efficacy of SAAE in patients with PA using ⁶⁸Ga-Pentixafor PET/CT, with the objective of establishing imaging evaluation methodologies for assessing PA patients post-SAAE treatment.</p><p><strong>Results: </strong>Of the 27 patients, 2 achieved complete clinical remission, while 25 experienced partial remission. Biochemically, 13 patients attained complete remission, 13 had partial remission, and 1 did not. For patients with aldosterone-producing adenoma, both visual and semi-quantitative analyses of PET/CT effectively assessed changes in radioactive uptake of the lesion. For idiopathic hyperaldosteronism patients, PET/CT parameters were more effective than visual analysis in evaluating SAAE efficacy. A significant difference in the ΔTLR-40 min parameter was observed across biochemical outcomes (P = 0.041), with patients having ΔTLR-40 min ≥ 0.07 showing better outcomes (AUC = 0.789, P = 0.041).</p><p><strong>Conclusions: </strong>⁶⁸Ga-Pentixafor PET/CT enables timely assessment of therapeutic outcomes in patients with PA following SAAE, thereby improving clinical decision-making and patient management.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"5"},"PeriodicalIF":3.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy.","authors":"Jan Heilinger, Katrin Sabine Roth, Henning Weis, Antonis Fink, Jasmin Weindler, Felix Dietlein, Philipp Krapf, Klaus Schomäcker, Bernd Neumaier, Markus Dietlein, Alexander Drzezga, Carsten Kobe","doi":"10.1186/s13550-024-01190-7","DOIUrl":"10.1186/s13550-024-01190-7","url":null,"abstract":"<p><strong>Background: </strong>In clinical practice, several radiopharmaceuticals are used for PSMA-PET imaging, each with distinct biodistribution patterns. This may impact treatment decisions and outcomes, as eligibility for PSMA-directed radioligand therapy is usually assessed by comparing tumoral uptake to normal liver uptake as a reference. In this study, we aimed to compare tracer uptake intraindividually in various reference regions including liver, parotid gland and spleen as well as the respective tumor-to-background ratios (TBR) of different ¹⁸F-labeled PSMA ligands to today's standard radiopharmaceutical ⁶⁸Ga-PSMA-11 in a series of patients with biochemical recurrence of prostate cancer who underwent a dual PSMA-PET examination as part of an individualized diagnostic approach.</p><p><strong>Results: </strong>Differences in background activity among different PSMA-PET tracers lead to variations in tumor-to-background ratios (TBR). In [¹⁸F]F-DCFPyL-PET, TBR with the liver as the reference organ (TBR_liver) was comparable to [⁶⁸Ga]Ga-PSMA-11-PET, while [¹⁸F]F-PSMA-1007-PET and [¹⁸F]F-JK-PSMA-7-PET showed significantly lower values. Using the parotid gland as the reference (TBR_parotidgland), [¹⁸F]F-DCFPyL-PET exhibited significantly higher values, whereas [¹⁸F]F-PSMA-1007-PET and [¹⁸F]F-JK-PSMA-7-PET were comparable. For the spleen (TBR_spleen), [¹⁸F]F-JK-PSMA-7-PET was comparable, but [¹⁸F]F-DCFPyL-PET and [¹⁸F]F-PSMA-1007-PET showed significantly higher and lower values, respectively. An additional Bland-Altman analyses revealed low bias for [¹⁸F]F-DCFPyL-PET in TBR_parotidgland, whereas significant differences in TBR_liver and TBR_spleen for the other tracers resulted in higher bias.</p><p><strong>Conclusion: </strong>Different PSMA-PET tracers exhibit distinct biodistribution patterns, leading to variations in tumor-to-background ratios (TBR) in reference organs such as the liver, parotid gland, and spleen. Patient selection for PSMA-directed radioligand therapy is currently based on a semiquantitative approach using the liver as a reference region in [⁶⁸Ga]Ga-PSMA-11-PET. Thus, the use of alternative [¹⁸F]-labeled tracers may result in under- or overestimation of a patient's suitability for therapy. This highlights the importance of a comprehensive understanding of the differences in tracer-specific uptake behavior for accurate decisions regarding PSMA-expression levels. However, as the patient cohort in this study is at earlier disease stages, the generalizability of these findings to later-stage patients remains unclear and requires further investigation.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"4"},"PeriodicalIF":3.1,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11723865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Quantification of [^99mTc]Tc-HDP bone SPECT/CT: can we improve the body weight based standardized uptake value with a more robust normalization?","authors":"Tiberiu Damian, Noel Spielhofer, Jakob Heimer, Alexander W Sauter, Cristina Popescu, Daniel Hausmann, Jason L Manser, Karim Eid, Rahel A Kubik-Huch, Irene A Burger","doi":"10.1186/s13550-024-01192-5","DOIUrl":"10.1186/s13550-024-01192-5","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"3"},"PeriodicalIF":3.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with ¹⁶⁶Ho-radioembolization : HBS in HCC treated with holmium-166.","authors":"Margot T M Reinders, Maarten J L Smits, Karel van Erpecum, Joep de Bruijne, Rutger C G Bruijnen, Dave Sprengers, Rob de Man, Erik Vegt, Jan N M IJzermans, Marnix G E H Lam, Arthur J A T Braat","doi":"10.1186/s13550-025-01196-9","DOIUrl":"10.1186/s13550-025-01196-9","url":null,"abstract":"<p><strong>Background: </strong>To study the feasibility of hepatobiliary scintigraphy (HBS) to improve selection and planning of patients with hepatocellular carcinoma (HCC) treated with holmium-166 (¹⁶⁶Ho)-microspheres radioembolization.</p><p><strong>Results: </strong>Thirty-one patients with HCC were included and treated with ¹⁶⁶Ho- radioembolization as part of a prospective phase 2 study. Twenty-seven patients were eligible for analysis, 67% had a cirrhotic liver morphology on imaging, 70% had multifocal disease and 51% had bilobar disease. None of the patients had clinical signs of liver decompensation (Child Pugh ≤ B7, median MELD 9 or ALBI - 2.55). Global and regional hepatic function was based on manual delineation of HBS using 200 MBq ^99mTc-mebrofenine, acquired during screening and approximately three months after ¹⁶⁶Ho-radioembolization, referred to as liver clearance rate (LCR). In line with LCR at baseline, a significant correlation was found between LCR and lab results, including bilirubin, albumin, ALT, MELD-score, and ALBI-score (p < 0.05) during follow-up. HBS showed a significant decrease in median LCR (-16%; p = 0.0017) and volume (-17%; p = 0.0027) in the treated liver, without a significant increase in the non-treated liver. Median relative change in overall LCR in non-cirrhotics was 0% (range - 23-33%), in cirrhotics - 10% (range - 40 - 19%; p = 0.40).</p><p><strong>Conclusion: </strong>HBS showed that hepatic function and volume significantly decreased in parts of the liver treated with ¹⁶⁶Ho-microspheres radioembolization in patients with HCC. Cirrhotic patients do not seem to have the capacity to increase hepatic function in the treated part of the liver.</p><p><strong>Trial registration: </strong>Registry name: Clinicaltrials.gov.</p><p><strong>Trial number: </strong>NCT03379844. Date of registration: 21 November 2017. Trial URL: https://clinicaltrials.gov/study/NCT03379844?cond=hcc&term=hepar primary&rank=1#study-overview .</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"2"},"PeriodicalIF":3.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}